Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ATNM

ATNM - Actinium Pharmaceuticals Inc Stock Price, Fair Value and News

6.74USD+0.08 (+1.20%)Market Closed
Watchlist

Market Summary

USD6.74+0.08
Market Closed
1.20%

ATNM Stock Price

View Fullscreen

ATNM RSI Chart

ATNM Valuation

Market Cap

184.8M

Price/Earnings (Trailing)

-3.68

Price/Sales (Trailing)

139.8

Price/Free Cashflow

-3.87

ATNM Price/Sales (Trailing)

ATNM Profitability

Return on Equity

-115.05%

Return on Assets

-56.37%

Free Cashflow Yield

-25.87%

ATNM Fundamentals

ATNM Revenue

Revenue (TTM)

1.1M

ATNM Earnings

Earnings (TTM)

-50.1M

Earnings Growth (Yr)

-40.13%

Earnings Growth (Qtr)

12.55%

Breaking Down ATNM Revenue

Last 7 days

16.7%

Last 30 days

23.9%

Last 90 days

41.9%

Trailing 12 Months

-51%

How does ATNM drawdown profile look like?

ATNM Financial Health

Current Ratio

9.87

ATNM Investor Care

Shares Dilution (1Y)

7.57%

Diluted EPS (TTM)

-1.93

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20221.5M1.2M1.1M0
20210001.1M
20200000
20190000
20180000
20170000
20160000
20150000
20140000
20130000
20120000
201121.5K17.5K13.6K9.6K
201000025.4K

Tracking the Latest Insider Buys and Sells of Actinium Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Aug 17, 2022
seth sandesh
acquired
-
-
300,000
chief executive officer
Mar 05, 2019
berger mark stanley
acquired
2,100
0.6
3,500
chief medical officer
Feb 21, 2019
seth sandesh
acquired
4,875
0.6
8,125
chairman & ceo

1–3 of 3

Which funds bought or sold ATNM recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 15, 2024
BARCLAYS PLC
added
710
165,000
192,000
-%
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
150,988
150,988
-%
Feb 15, 2024
Legal & General Group Plc
added
16.75
27.00
15,331
-%
Feb 14, 2024
D. E. Shaw & Co., Inc.
sold off
-100
-106,572
-
-%
Feb 14, 2024
DEUTSCHE BANK AG\
reduced
-6.94
-18,166
72,025
-%
Feb 14, 2024
STATE STREET CORP
reduced
-3.09
-521,356
2,574,760
-%
Feb 14, 2024
GROUP ONE TRADING, L.P.
new
-
25,603
25,603
-%
Feb 14, 2024
Metropolitan Life Insurance Co/NY
unchanged
-
-1,204
7,285
-%
Feb 14, 2024
BANK OF AMERICA CORP /DE/
added
19.42
6,082
251,632
-%
Feb 14, 2024
Coppell Advisory Solutions LLC
new
-
36.00
36.00
-%

1–10 of 44

Are Funds Buying or Selling ATNM?

Are funds buying ATNM calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ATNM
No. of Funds

Unveiling Actinium Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2024
bigger capital, llc
1.6%
441,104
SC 13G/A
Jan 29, 2024
blackrock inc.
6.2%
1,691,914
SC 13G
Feb 06, 2023
bigger capital fund l p
1.6%
416,000
SC 13G/A
Feb 09, 2022
bigger capital fund l p
1.5%
323,236
SC 13G/A
Feb 12, 2021
bigger capital fund l p
2.1%
292,729
SC 13G/A
Jan 05, 2021
sabby management, llc
4.64%
630,637
SC 13G/A
Aug 12, 2020
bigger capital fund l p
2.1%
287,730
SC 13G
May 01, 2020
sabby management, llc
7.29%
20,095,255
SC 13G
Apr 27, 2020
bigger capital fund l p
1.7%
6,448,693
SC 13G/A
Feb 14, 2020
bigger capital fund l p
1.9%
3,191,979
SC 13G/A

Recent SEC filings of Actinium Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Feb 09, 2024
SC 13G/A
Major Ownership Report
Feb 05, 2024
EFFECT
EFFECT
Feb 02, 2024
S-3/A
S-3/A
Jan 29, 2024
SC 13G
Major Ownership Report
Dec 29, 2023
4
Insider Trading
Dec 29, 2023
4
Insider Trading
Dec 29, 2023
4
Insider Trading
Dec 29, 2023
4
Insider Trading
Dec 29, 2023
4
Insider Trading
Dec 29, 2023
4
Insider Trading

Peers (Alternatives to Actinium Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.9B
9.1B
-16.59% -47.80%
-10.94
4.16
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
20.5B
1.8B
-23.99% -31.71%
-46.58
11.22
76.23% 61.08%
16.9B
2.3B
-4.89% -18.90%
115.27
7.33
15.05% 75.21%
13.7B
3.7B
-7.62% -26.87%
22.88
3.7
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.22
29.35
141.38% 4.43%
6.5B
-
-3.85% 226.12%
-10.45
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-18.87
17.04
-35.86% -26.24%
3.7B
240.7M
-19.08% -10.99%
-12.61
15.54
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.89
4.25
81.69% -7.29%
579.7M
1.0B
-9.17% -57.89%
-1.06
0.55
-43.15% 58.48%
174.3M
4.9M
-14.18% -58.18%
-1.06
35.65
-57.57% 50.48%
112.6M
881.7K
289.54% 381.25%
-2.37
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Actinium Pharmaceuticals Inc News

Latest updates
InvestorsObserver20 Feb 202406:11 pm

Actinium Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q32021Q22021Q22020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q12017Q42017Q3
Revenue0%45.0045.0094023.00233266---------------
Operating Expenses24.7%9,8447,8956,1048,0716,7025,341-6,4355,6134,6625,6834,6356,6525,0865,699------
  S&GA Expenses-4.9%3,0733,2331,7352,6551,9941,710-1,7971,8251,1541,5321,2611,8221,0761,363------
  R&D Expenses45.2%6,7714,6624,3695,4164,7083,631-4,6393,7883,5084,1513,3744,8304,0104,336------
Interest Expenses291.6%32583.0035.0038.0046.0054.00-55.0073.0037.0013.0031.0053.0059.0029.00------
Net Income-22.0%-9,474-7,767-5,129-8,010-6,423-5,021--6,380-5,540-4,625-5,670-4,603-6,599-5,027-5,670------
Net Income Margin-31.0%-28.85*-22.02*-16.81*-21.66*-2.41-2.32-2.27-2.31-2.13------------
Free Cashflow-120.9%-5,78827,648-5,788-5,052-5,656-4,645-5,646-6,503-4,999------------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-10.2%89.0099.0010211411712275.0080.0084.0084.0075.0066.0051.0056.008.0012.0016.0022.0012.0015.0016.00
  Current Assets-10.4%86.0096.0099.0011111311874.0080.0083.0083.0074.0065.0049.0055.007.0010.0015.0020.0010.0014.0015.00
    Cash Equivalents-9.1%83.0091.0095.0010911311772.0078.0082.0082.0073.0064.0049.0054.006.0010.0015.0020.0010.0014.0015.00
  Net PPE-3.7%1.001.001.001.001.001.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
Liabilities-1.3%45.0046.0045.0048.0046.0044.006.007.004.004.004.005.005.005.005.006.006.006.007.006.004.00
  Current Liabilities-5.2%9.009.008.0011.008.006.006.007.004.004.004.005.005.005.005.005.006.005.006.006.004.00
Shareholder's Equity-17.9%44.0053.0057.0066.0071.0078.0069.0074.0080.0080.0071.0061.0045.0051.003.006.0010.0016.005.009.0012.00
  Retained Earnings-4.2%-328-314-299-288-278-268-260-255-247-241-236-230-224-219-214-208-204-197-192-186-180
  Additional Paid-In Capital1.0%372368357355349347330329328322307292270270217214214213198196192
Accumulated Depreciation9.0%1.001.001.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
Shares Outstanding1.6%27.0027.0026.0026.0024.0024.0022.0022.0020.0019.0019.0018.0015.00--------
Float------120---139---139---40.00---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations18.5%-11,125-13,643-15,077-7,778-5,71527,918-5,781-5,052-5,588-4,584-5,642-6,258-4,994-4,511-5,854-5,011-5,598-5,364-5,489-4,286-6,614
  Share Based Compensation-8.0%9211,001993979970425421448411459376384288210372311391277316387406
Cashflow From Investing36.2%-30.00-47.00-76.00-16.00-73.00-270-7.00--68.00-61.00-4.00-245----5.00--8.00-51.00-10.57-58.71
Cashflow From Financing-71.5%2,86010,0487704,8931,57516,663-22.008015,77614,30414,34021,829-23052,0352,542-44.0035015,0161,7923,1664.00

ATNM Income Statement

2023-09-30
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue    
Revenue
Other revenue451,030
Total revenue451,030
Operating expenses:    
Research and development, net of reimbursements11,6226,77130,55215,802
General and administrative2,7293,07311,0258,041
Total operating expenses14,3519,84441,57723,843
Loss from operations(14,351)(9,799)(41,577)(22,813)
Other income:    
Interest income - net1,0753252,083443
Total other income1,0753252,083443
Net loss$ (13,276)$ (9,474)$ (39,494)$ (22,370)
Net loss per common share – basic (in Dollars per share)$ (0.49)$ (0.38)$ (1.5)$ (0.94)
Weighted average common shares outstanding – basic (in Shares)27,058,39725,164,59926,329,29823,691,218

ATNM Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current Assets:  
Cash and cash equivalents$ 82,978$ 108,910
Restricted cash - current396
Prepaid expenses and other current assets2,6181,636
Total Current Assets85,596110,942
Property and equipment, net of accumulated depreciation of $643 and $487601604
Restricted cash – long term310302
Operating leases right-of-use assets2,4362,341
Finance leases right-of-use assets13
Total Assets88,944114,192
Current Liabilities:  
Accounts payable and accrued expenses8,15010,130
Operating leases current liability521494
Finance leases current liability14
Total Current Liabilities8,67210,628
Long-term license revenue deferred35,00035,000
Long-term operating lease obligations1,6892,083
Total Liabilities45,36147,711
Commitments and contingencies
Stockholders’ Equity:  
Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding
Common stock, $0.001 par value; 1,000,000,000 shares authorized; 27,413,441 and 25,674,823 shares issued and outstanding, respectively2726
Additional paid-in capital371,815355,220
Accumulated deficit(328,259)(288,765)
Total Stockholders’ Equity43,58366,481
Total Liabilities and Stockholders’ Equity$ 88,944$ 114,192
ATNM
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.
 CEO
 WEBSITEwww.actiniumpharma.com
 EMPLOYEES49

Actinium Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Actinium Pharmaceuticals Inc? What does ATNM stand for in stocks?

ATNM is the stock ticker symbol of Actinium Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Actinium Pharmaceuticals Inc (ATNM)?

As of Thu Feb 22 2024, market cap of Actinium Pharmaceuticals Inc is 184.77 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ATNM stock?

You can check ATNM's fair value in chart for subscribers.

What is the fair value of ATNM stock?

You can check ATNM's fair value in chart for subscribers. The fair value of Actinium Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Actinium Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ATNM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Actinium Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ATNM is over valued or under valued. Whether Actinium Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Actinium Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATNM.

What is Actinium Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, ATNM's PE ratio (Price to Earnings) is -3.68 and Price to Sales (PS) ratio is 139.8. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ATNM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Actinium Pharmaceuticals Inc's stock?

In the past 10 years, Actinium Pharmaceuticals Inc has provided -0.279 (multiply by 100 for percentage) rate of return.